Literature DB >> 173959

Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.

F A McElroy, R B Philip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 173959     DOI： 10.1016/0024-3205(75)90170-8

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  7 in total

1.  Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative.

Authors:  J J Killackey; B A Killackey; R B Philp
Journal:  Agents Actions       Date:  1985-12

2.  Adenosine transporter antagonism in humans augments vasodilator responsiveness to adenosine, but not exercise, in both adenosine responders and non-responders.

Authors:  Elizabeth A Martin; Wayne T Nicholson; Timothy B Curry; John H Eisenach; Nisha Charkoudian; Michael J Joyner
Journal:  J Physiol       Date:  2006-12-07       Impact factor: 5.182

Review 3.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

4.  Failure of orally administered RA233 to influence B16 melanoma growth or metastasis.

Authors:  C W Stackpole; D M Fornabaio; A L Alterman
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

5.  Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time.

Authors:  E Tremoli; L Bertoli; R Merlini; S Colli; P Maderna; O Mantero; C R Sirtori
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  Enhanced prostacyclin production by dipyridamole in man.

Authors:  G G Neri Serneri; G Masotti; L Poggesi; G Galanti; A Morettini
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.

Authors:  G A Rongen; P Smits; K Ver Donck; J J Willemsen; R A De Abreu; H Van Belle; T Thien
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.